Patents by Inventor Gail E. Atkinson

Gail E. Atkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • p21 peptides
    Patent number: 7449544
    Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: November 11, 2008
    Assignee: Cyclacel Limited
    Inventors: Daniella I. Zheleva, Peter Martin Fischer, Campbell McInnes, Martin J. I. Andrews, Weng C. Chan, Gail E. Atkinson
  • p21 peptides
    Publication number: 20040176301
    Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
    Type: Application
    Filed: May 19, 2003
    Publication date: September 9, 2004
    Applicant: Cyclacel Limited
    Inventors: Daniella I. Zheleva, Peter M. Fischer, Campbell McInnes, Martin J.I. Andrews, Weng C. Chan, Gail E. Atkinson
  • p21 peptides
    Publication number: 20030036628
    Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
    Type: Application
    Filed: November 29, 2000
    Publication date: February 20, 2003
    Inventors: Daniella I. Zheleva, Peter M. Fischer, Campbell McInnes, Martin J.I. Andrews, Weng C. Chan, Gail E. Atkinson